<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856140</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-RM-SGChung-ASC-01</org_study_id>
    <nct_id>NCT01856140</nct_id>
  </id_info>
  <brief_title>Treatment of Tendon Injury Using Mesenchymal Stem Cells</brief_title>
  <acronym>ALLO-ASC</acronym>
  <official_title>Treatment of Tendon Injury Using Allogenic Adipose-derived Mesenchymal Stem Cells(ALLO-ASC):A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Main purpose of this study is to evaluate efficacy and safety of allogenic adipose-derived
      mesenchymal stem cells(ALLO-ASC) in treatment of tendon injury. ALLO-ASC will be
      administrated to the patients with lateral epicondylitis by ultrasonographic guided
      injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Injection volume depends on the size of lesion on ultrasound examination. And all injection
      will be done under ultrasound guidance. First the investigators will administrate 1 million
      cells/ml (Group 1 for 6 participants). After monitoring the safety of injection for 2 weeks
      (the investigators will use WHO recommendations for grading of acute and subacute toxic
      effects), the investigators decide to increase the quantity as 10 million cells/ml (Group 2
      for participants).

      The investigators will compare the efficacy difference as quantity increase. For efficacy
      measurement, VAS/modified Mayo clinic performance index for elbow/lesion measurement by
      ultrasound will be used at 6 and 12 weeks after injections.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Visual analog scale (VAS) at 6 and 12 weeks</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks after intervention</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Lateral Epicondylitis</condition>
  <arm_group>
    <arm_group_label>1 million cells/ml of ALLO-ASC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 million cells/ml of ALLO-ASC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10 million cells/ml of ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) will be injected by ultrasound guided intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection</intervention_name>
    <arm_group_label>1 million cells/ml of ALLO-ASC</arm_group_label>
    <arm_group_label>10 million cells/ml of ALLO-ASC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinically diagnosed as lateral epicondylitis (tennis elbow)

          -  recurrent pain in spite of conservative treatment such as physical therapy,
             medication, steroid injection

          -  symptom duration is over 6 months

          -  defect in common extensor tendon can be observed under ultrasound

          -  patient that can understand the clinical trials

        Exclusion Criteria:

          -  patient that underwent other injection treatment within 6 weeks

          -  some associated diseases (such as arthritis, synovitis, entrapment of related nerve,
             radiculopathy to the target lesion, generalized pain syndrome, rheumatoid arthritis,
             pregnancy, impaired sensibility, paralysis, history of allergic or hypersensitive
             reaction to bovine-derived proteins or fibrin glue)

          -  patient that enrolled other clinical trials within 30 days

          -  history of drug/alcohol addiction, habitual smoker
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sun Gun Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sun Gun Chung, MD, PhD</last_name>
    <phone>+82-2-2072-3954</phone>
    <email>suncg@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sang Yoon Lee, MD, MS</last_name>
    <phone>+82-2-2072-2967</phone>
    <email>rehabilee@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sun Gun Chung, MD, PhD</last_name>
      <phone>+82-2-2072-3954</phone>
      <email>suncg@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sun Gun Chung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Coombes BK, Bisset L, Vicenzino B. Efficacy and safety of corticosteroid injections and other injections for management of tendinopathy: a systematic review of randomised controlled trials. Lancet. 2010 Nov 20;376(9754):1751-67. doi: 10.1016/S0140-6736(10)61160-9. Epub 2010 Oct 21. Review.</citation>
    <PMID>20970844</PMID>
  </reference>
  <reference>
    <citation>Price R, Sinclair H, Heinrich I, Gibson T. Local injection treatment of tennis elbow--hydrocortisone, triamcinolone and lignocaine compared. Br J Rheumatol. 1991 Feb;30(1):39-44.</citation>
    <PMID>1991216</PMID>
  </reference>
  <reference>
    <citation>Sánchez M, Azofra J, Anitua E, Andía I, Padilla S, Santisteban J, Mujika I. Plasma rich in growth factors to treat an articular cartilage avulsion: a case report. Med Sci Sports Exerc. 2003 Oct;35(10):1648-52.</citation>
    <PMID>14523300</PMID>
  </reference>
  <reference>
    <citation>Johnson GW, Cadwallader K, Scheffel SB, Epperly TD. Treatment of lateral epicondylitis. Am Fam Physician. 2007 Sep 15;76(6):843-8. Review.</citation>
    <PMID>17910298</PMID>
  </reference>
  <reference>
    <citation>Sölveborn SA, Buch F, Mallmin H, Adalberth G. Cortisone injection with anesthetic additives for radial epicondylalgia (tennis elbow). Clin Orthop Relat Res. 1995 Jul;(316):99-105.</citation>
    <PMID>7634730</PMID>
  </reference>
  <reference>
    <citation>Maffulli N, Longo UG, Denaro V. Novel approaches for the management of tendinopathy. J Bone Joint Surg Am. 2010 Nov 3;92(15):2604-13. doi: 10.2106/JBJS.I.01744. Review.</citation>
    <PMID>21048180</PMID>
  </reference>
  <reference>
    <citation>Mishra A, Pavelko T. Treatment of chronic elbow tendinosis with buffered platelet-rich plasma. Am J Sports Med. 2006 Nov;34(11):1774-8. Epub 2006 May 30.</citation>
    <PMID>16735582</PMID>
  </reference>
  <reference>
    <citation>Kon E, Filardo G, Delcogliano M, Presti ML, Russo A, Bondi A, Di Martino A, Cenacchi A, Fornasari PM, Marcacci M. Platelet-rich plasma: new clinical application: a pilot study for treatment of jumper's knee. Injury. 2009 Jun;40(6):598-603. doi: 10.1016/j.injury.2008.11.026. Epub 2009 Apr 19.</citation>
    <PMID>19380129</PMID>
  </reference>
  <reference>
    <citation>Sánchez M, Anitua E, Azofra J, Andía I, Padilla S, Mujika I. Comparison of surgically repaired Achilles tendon tears using platelet-rich fibrin matrices. Am J Sports Med. 2007 Feb;35(2):245-51. Epub 2006 Nov 12.</citation>
    <PMID>17099241</PMID>
  </reference>
  <reference>
    <citation>Slater M, Patava J, Kingham K, Mason RS. Involvement of platelets in stimulating osteogenic activity. J Orthop Res. 1995 Sep;13(5):655-63.</citation>
    <PMID>7472743</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <last_update_submitted>November 22, 2013</last_update_submitted>
  <last_update_submitted_qc>November 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Sun Gun Chung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>adipose derived mesenchymal stem cell</keyword>
  <keyword>allogeneic stem cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tennis Elbow</mesh_term>
    <mesh_term>Tendon Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

